4F-MDMB-BINACA

Risk assessment report on a new psychoactive substance: methyl 2-{[1-(4-fluorobutyl)-1H-indole-3-carbonyl]amino}-3,3-dime- thylbutanoate (4F-MDMB-BICA) in accordance with Article 5c of Regulation (EC) No 1920/2006 (as amended)

Retrieved on: 
Saturday, March 13, 2021
Designer drugs, Cannabinoids, Organofluorides, European Monitoring Centre for Drugs and Drug Addiction, European Union, 4F-MDMB-BINACA, Risk, Chemistry, Physical sciences, Articles

This risk assessment report presents the summary findings and the conclusion of the risk assessment carried out by the Scientific Committee of the EMCDDA on 4F-MDMB-BICA.

Key Points: 
  • This risk assessment report presents the summary findings and the conclusion of the risk assessment carried out by the Scientific Committee of the EMCDDA on 4F-MDMB-BICA.
  • The report is intended for policymakers and decision-makers in the institutions of the EU.
  • Explanatory note: In the interests of public health protection the EMCDDA is releasing this report before formal copy editing and page layout in the EMCDDA house style.
  • The final report will be available in due course.

European Commission proposes to control two harmful new psychoactive substances

Retrieved on: 
Saturday, March 13, 2021
Psychoactive drugs, Designer drugs, Cannabinoids, 4F-MDMB-BINACA, MDMB-4en-PINACA, Synthetic cannabinoids, 5F-EMB-PINACA, MDMB-FUBICA

Today, the European Commission has proposed to control two harmful new psychoactive substances (NPS) across the European Union.

Key Points: 
  • Today, the European Commission has proposed to control two harmful new psychoactive substances (NPS) across the European Union.
  • The substances in question MDMB-4en-PINACA and 4F-MDMB-BICA are both synthetic cannabinoids, which have been raising health concerns in Europe (1).
  • The proposal to control the substances is based on risk assessments conducted by the EU drugs agency (EMCDDA) in December 2020.
  • The substances have been detected in smoking mixtures, powders, liquids (including e-liquids) and paper impregnated with the substance (including blotters).

EMCDDA technical report on the new psychoactive substance methyl 2-{[1-(4-fluorobutyl)-1H-indole-3-carbonyl]amino}-3,3-dimethylbutanoate (4F-MDMB-BICA)

Retrieved on: 
Tuesday, December 22, 2020
Cannabinoids, Designer drugs, Chemistry, Organic compounds, Organic chemistry, 4F-MDMB-BINACA, MDMB-FUBINACA, MDMB-FUBICA

The purpose of this technical report is to provide an analysis of the available information on methyl 2-{[1-(4-fluorobutyl)-1H-indole-3-carbonyl]amino}-3,3-dimethylbutanoate (commonly known as 4F-MDMB-BICA), a synthetic receptor cannabinoid agonist that has recently emerged on the drug market in Europe, in order to support the risk assessment of the substance which has been requested by the European Commission in accordance with Article 5c of Regulation (EC) No 1920/2006 (as amended).

Key Points: 
  • The purpose of this technical report is to provide an analysis of the available information on methyl 2-{[1-(4-fluorobutyl)-1H-indole-3-carbonyl]amino}-3,3-dimethylbutanoate (commonly known as 4F-MDMB-BICA), a synthetic receptor cannabinoid agonist that has recently emerged on the drug market in Europe, in order to support the risk assessment of the substance which has been requested by the European Commission in accordance with Article 5c of Regulation (EC) No 1920/2006 (as amended).
  • Explanatory note: In the interests of public health protection the EMCDDA is releasing this report before formal copy editing and page layout in the EMCDDA house style.
  • The final report will be available in due course.